Try our Advanced Search for more refined results

Expert Analysis

Allergan Fuels Tension Over Schedule 13D Disclosure

Law360, New York ( February 23, 2015, 10:36 AM EST) -- Valeant Pharmaceuticals International Inc. and Pershing Square Capital Management LP's hostile bid for Allergan Inc. seems to have run its course following the announcement of the proposed acquisition of Allergan by Actavis PLC — but not before the U.S. District Court for the Central District of California (Southern Division), the court hearing Allergan's lawsuit alleging that Valeant and Pershing Square engaged in insider trading by purchasing shares of Allergan in violation of Rule 14e-3 under the Exchange Act, shed light on two key aspects of that rule....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Law Firms

Companies

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!